Zhi Fan - Luye Pharma Chief Ltd
| LYPHF Stock | USD 0.34 0.00 0.00% |
Executive
Zhi Fan is Chief Ltd of Luye Pharma Group
| Web | https://www.luye.cn |
Luye Pharma Management Efficiency
Luye Pharma's management efficiency ratios could be used to measure how well Luye Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Giovanni MD | Bristol Myers Squibb | 59 | |
| Linda MD | Novartis AG ADR | 61 | |
| Susan Silbermann | Pfizer Inc | 63 | |
| FMedSci MD | Pfizer Inc | 61 | |
| Annette Doherty | Pfizer Inc | N/A | |
| Kimberly Jablonski | Bristol Myers Squibb | N/A | |
| Pierre Chancel | Sanofi ADR | 68 | |
| Chirfi Guindo | Merck Company | 58 | |
| Jessica Moore | Johnson Johnson | N/A | |
| Sumant Rajendran | Scilex Holding | N/A | |
| Peter Fishman | Amarin PLC | N/A | |
| Deborah JD | Gilead Sciences | 60 | |
| Ruth March | AstraZeneca PLC ADR | N/A | |
| Linda Higgins | Gilead Sciences | 63 | |
| Latif MD | AbbVie Inc | N/A | |
| Deborah Telman | Gilead Sciences | 59 | |
| Robert Weltevreden | Novartis AG ADR | 52 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Ahn Poole | Bristol Myers Squibb | 50 | |
| Duane Arsdale | Johnson Johnson | N/A | |
| Flavius MD | Gilead Sciences | N/A | |
Management Performance
| Return On Equity | -0.0261 | |||
| Return On Asset | 0.0081 |
Luye Pharma Group Leadership Team
Elected by the shareholders, the Luye Pharma's board of directors comprises two types of representatives: Luye Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Luye. The board's role is to monitor Luye Pharma's management team and ensure that shareholders' interests are well served. Luye Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Luye Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rong Yang, CoFounder Chairman | ||
| Yuan Liu, Chief Officer | ||
| Yuan Zhu, Ex Director | ||
| Yun Xue, VP Luye | ||
| Li Loh, Assistant Sec | ||
| Dian Liu, Exec CoFounder | ||
| Hui Yuan, CoFounder Director | ||
| ACIS ACS, Company Sec | ||
| Zhi Fan, Chief Ltd | ||
| You Li, Head VP |
Luye Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Luye Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0261 | |||
| Return On Asset | 0.0081 | |||
| Profit Margin | (0.04) % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 3.55 B | |||
| Shares Owned By Insiders | 35.41 % | |||
| Shares Owned By Institutions | 24.08 % | |||
| Price To Book | 2.17 X | |||
| Price To Sales | 0.47 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Luye Pink Sheet
Luye Pharma financial ratios help investors to determine whether Luye Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Luye with respect to the benefits of owning Luye Pharma security.